Whitehawk Therapeutics, Inc. (WHWK) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Seven of eight analysts rate Whitehawk Therapeutics a buy, while one recommends selling. The average 12-month price target is $8.33 versus the stock’s recent price of $3.24.
• Whitehawk shares remain well below their 12-month high of $5.49 and are trading below both their 50-day and 200-day moving averages, while the company remains unprofitable with a negative P/E ratio.
• The clinical-stage biopharmaceutical company beat quarterly EPS expectations, reporting a loss of $0.20 per share versus the $0.30 consensus loss. Institutional investors and hedge funds own approximately 52.08% of the stock.

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.33.

WHWK has been the topic of a number of research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Stifel Nicolaus initiated coverage on Whitehawk Therapeutics in a report on Wednesday, September 30th. They set a "buy" rating and a $9.00 price target for the company. Wall Street Zen upgraded Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Leerink Partners assumed coverage on shares of Whitehawk Therapeutics in a research report on Monday, July 13th. They set an "outperform" rating and a $9.00 price target for the company.

Whitehawk Therapeutics Price Performance

NASDAQ:WHWK opened at $3.24 on Monday. The firm's fifty day simple moving average is $3.86 and its 200 day simple moving average is $3.83. The stock has a market cap of $184.71 million, a P/E ratio of -2.89 and a beta of 0.99. Whitehawk Therapeutics has a twelve month low of $1.97 and a twelve month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. On average, analysts expect that Whitehawk Therapeutics will post -1.00 EPS for the current fiscal year.

Institutional Trading of Whitehawk Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in WHWK. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics during the 1st quarter valued at about $40,000. Two Sigma Securities LLC acquired a new stake in shares of Whitehawk Therapeutics during the 2nd quarter worth approximately $46,000. Deutsche Bank AG bought a new stake in shares of Whitehawk Therapeutics in the 2nd quarter valued at $145,000. Bank of America Corp DE bought a new position in shares of Whitehawk Therapeutics during the 2nd quarter worth approximately $159,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Whitehawk Therapeutics during the 1st quarter worth about $187,000. 52.08% of the stock is owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company's activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company's specific pipeline, operating geographies and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.